AlloVir, Inc. (ALVR) Stock

About AlloVir, Inc.

AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.

AlloVir, Inc. is headquartered in US.

AlloVir, Inc. (ALVR) stock trades at $9.81 with a market capitalization of $49.48M. The stock is valued at a negative price-to-earnings (P/E) ratio of -1.89, reflecting a net loss over the last twelve months, price-to-book of 1.41, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $7.96 and $24.15, and currently trades 59.4% below its 52-week high.

On profitability, AlloVir, Inc. generates a return on equity (ROE) of -72.78% (negative, reflecting a net loss), return on capital employed of -46.82%.

Official website: www.allovir.com